MNG1295
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.347
- APICAL_SURFACE+0.298
- MYOGENESIS+0.258
- APICAL_JUNCTION+0.172
- KRAS_SIGNALING_DN+0.169
- XENOBIOTIC_METABOLISM+0.147
- UV_RESPONSE_DN+0.143
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.130
- ESTROGEN_RESPONSE_EARLY+0.111
- PANCREAS_BETA_CELLS+0.106
Top 10 suppressed
- MYC_TARGETS_V1-0.495
- MYC_TARGETS_V2-0.494
- OXIDATIVE_PHOSPHORYLATION-0.460
- PROTEIN_SECRETION-0.393
- UNFOLDED_PROTEIN_RESPONSE-0.390
- E2F_TARGETS-0.385
- MTORC1_SIGNALING-0.364
- G2M_CHECKPOINT-0.352
- MITOTIC_SPINDLE-0.318
- INFLAMMATORY_RESPONSE-0.311
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1396640 | GTEX | — | 0.893 |
| 2 | SRR1499193 | GTEX | — | 0.890 |
| 3 | s0095205 | — | — | 0.884 |
| 4 | SRR1331751 | GTEX | — | 0.882 |
| 5 | SRR1471350 | GTEX | — | 0.878 |
| 6 | MNG532 | — | — | 0.877 |
| 7 | SRR1311575 | GTEX | — | 0.875 |
| 8 | C3L-01890 | — | cohortA2 | 0.874 |
| 9 | SRR1406976 | GTEX | — | 0.867 |
| 10 | MNG4 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.347 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.298 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.258 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.172 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.169 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.147 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.143 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.111 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.106 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.092 | Idelalisib | — uncovered |
| PEROXISOME | 0.083 | Idelalisib | — uncovered |
| COAGULATION | 0.078 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.077 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.054 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.020 | Remibrutinib | — uncovered |